hrcak mascot   Srce   HID

Izvorni znanstveni članak

Our Experience of Melanoma Thickness as a Predictor of Outcome of Sentinel Node Biopsy

Damir Homolak
Borki Vučetić
Zvonimir Puljiz
Iva Blajić
Maja Vurnek Živković
Mirna Šitum

Puni tekst: engleski, pdf (57 KB) str. 57-60 preuzimanja: 624* citiraj
APA 6th Edition
Homolak, D., Vučetić, B., Puljiz, Z., Blajić, I., Vurnek Živković, M. i Šitum, M. (2008). Our Experience of Melanoma Thickness as a Predictor of Outcome of Sentinel Node Biopsy. Collegium antropologicum, 32 - Supplement 2 (2), 57-60. Preuzeto s https://hrcak.srce.hr/34541
MLA 8th Edition
Homolak, Damir, et al. "Our Experience of Melanoma Thickness as a Predictor of Outcome of Sentinel Node Biopsy." Collegium antropologicum, vol. 32 - Supplement 2, br. 2, 2008, str. 57-60. https://hrcak.srce.hr/34541. Citirano 28.07.2021.
Chicago 17th Edition
Homolak, Damir, Borki Vučetić, Zvonimir Puljiz, Iva Blajić, Maja Vurnek Živković i Mirna Šitum. "Our Experience of Melanoma Thickness as a Predictor of Outcome of Sentinel Node Biopsy." Collegium antropologicum 32 - Supplement 2, br. 2 (2008): 57-60. https://hrcak.srce.hr/34541
Harvard
Homolak, D., et al. (2008). 'Our Experience of Melanoma Thickness as a Predictor of Outcome of Sentinel Node Biopsy', Collegium antropologicum, 32 - Supplement 2(2), str. 57-60. Preuzeto s: https://hrcak.srce.hr/34541 (Datum pristupa: 28.07.2021.)
Vancouver
Homolak D, Vučetić B, Puljiz Z, Blajić I, Vurnek Živković M, Šitum M. Our Experience of Melanoma Thickness as a Predictor of Outcome of Sentinel Node Biopsy. Collegium antropologicum [Internet]. 2008 [pristupljeno 28.07.2021.];32 - Supplement 2(2):57-60. Dostupno na: https://hrcak.srce.hr/34541
IEEE
D. Homolak, B. Vučetić, Z. Puljiz, I. Blajić, M. Vurnek Živković i M. Šitum, "Our Experience of Melanoma Thickness as a Predictor of Outcome of Sentinel Node Biopsy", Collegium antropologicum, vol.32 - Supplement 2, br. 2, str. 57-60, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/34541. [Citirano: 28.07.2021.]

Sažetak
All follow up protocols for patients with malignant melanoma (MM) are oriented to early detection of metastases. As
most of the relapses happened in regional lymph nodes, special attention is given to this region, using different diagnostic
tools. Sentinel lymph node biopsy (SLNB) is generally accepted method in determining status of lymph nodes in MM
patients, in their staging. This method provides valuable prognostic information, facilitates early therapeutical lymphadenectomy
and so provides good base for identification of those patients who are candidates for different adjuvant modalities
of treatment. (In 2001 American Joint Committee on Cancer introduced new staging system for melanoma patients
which presents good frame for prognosis and therapeutical approach. Inclusion of new criteria will allow better
and more individualized prognosis and treatment.) The most important predictor of SLNB outcome is thickness of tumor
according to Breslow, while there is no sufficient data to show correlation with other factors.We retrospectively studded
431 patients, out of which SLNB was performed on 188. Forty patients or 21.3% had positive lymph nodes. Our results
showed strong correlation of tumor thickness and Clark level of invasion with SLNB outcome. Metastatic lymph
nodes were founded in all acral-lentiginous melanoma patients, followed by nodular melanoma – 55.6% and superficial
spreading melanoma – 14.1%. Results showed statistically significant predilection of positive SLNB in male patients
and no correlation of positive SLNB with histological type of tumor. On the contrary, it showed significant correlation
with development of metastases. Thus our results are similar to other comparable studies.

Ključne riječi
malignant melanoma; sentinel lymph node biopsy; melanoma thickness

Hrčak ID: 34541

URI
https://hrcak.srce.hr/34541

Posjeta: 891 *